Syöpätautien klinikka

Julkaisut 2009
Publications 2009

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Abdalla F et al. Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis.
2 Bono P et al. Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial.
3 Branca M, Syrjänen KJ. Novel biomarkers as predictors of CIN lesions and prognosis of cervical cancer.
4 Buhmeida A et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma.
5 Buhmeida A et al. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
6 Buhmeida A et al. DNA image cytometry predicts disease outcome in Stage II colorectal carcinoma.
7 Costa S et al. Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up.
8 Grönroos T et al. Imaging of hypoxia with PET-CT.
9 Guarisi R et al. Smoking worsens the prognosis of mild abnormalities in cervical cytology.
10 Hollmén M et al. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms.
11 Högel H, Jaakkola P. Hypoksia ja sen merkitys syövässä.
12 Ibrahim N et al. The potential value of EGFR and P53 immunostaining in tumors of the urinary bladder.
13 Iivanainen E et al. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
14 Jaakkola PM, Pursiheimo J-P. p62 degradation by autophagy.
15 Joensuu H et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial.
16 Kankuri-Tammilehto M. Prognostic Markers and Prolonged Interferon-alfa Therapy In Renal Cell Carcinoma.
17 Kauhanen S et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
18 Kauhanen SP et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
19 Komar G et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness.
20 Komar G et al. Comparison of 2D and 3D performance for FDG PET with different acquisition times in oncological patients.
21 Korkeila E et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.
22 Korkeila E et al. Reply: expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer.
23 Koskivuo IO et al. Head and neck cutaneous melanoma: a retrospective observational study on 146 patients.
24 Latvala A et al. Anaemia and other predictors of fatigue among patients on palliative therapy for advanced cancer.
25 Lindholm P. Ruuansulatuskanavan tukikudosten metastasoineiden pahanlaatuisten kasvainten (GIST) hoito.
26 Lindholm P et al. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer.
27 Lindholm P et al. The role of PET/CT and current challenges in prostate cancer management.
28 Lindroos MM et al. Cerebral oxygen and glucose metabolism in patients with mitochondrial m.3243A>G mutation .
29 Lindström AK et al. Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
30 Luukkaa M et al. Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck.
31 Martinez EZ et al. Bayesian estimation of performance measures of screening tests in the presence of covariates and absence of a gold standard.
32 Minn H et al. 18F-FDOPA: A multiple-target molecule.
33 Muraoka-Cook RS et al. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
34 Peltola K et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.
35 Pitta DR et al. Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region.
36 Pursiheimo J-P et al. Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62.
37 Ristamäki R et al. Hepatosellulaarisen karsinooman hoito.
38 Ryhänen AM et al. Evaluation of written patient educational materials in the field of diagnostic imaging .
39 Sarian LO et al. Increased risk of oncogenic human papillomavirus infections and incident high-grade cervical intraepithelial neoplasia among smokers.
40 Sarkola ME et al. Effect of second pregnancy on maternal carriage and outcome of high-risk human papillomavirus (HPV).
41 Seppälä J et al. Major reduction of monitor units with the avoidance of leaf-sequencing step by direct aperture based IMRT optimisation.
42 Seppälä J et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.
43 Simen-Kapeu A et al. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure.
44 Syrjänen K. Histology, classification and natural history of cervical intraepithelial neoplasia (CIN).
45 Syrjänen K. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
46 Syrjänen K. Annual disease burden due to human papillomavirus (HPV) 16 and 18 infections in Finland.
47 Syrjänen K. Human papillomavirus (HPV) involvement in esophageal carcinogenesis.
48 Syrjänen K et al. Reproducibility of classification and correction for verification bias as determinants of performance of Papanicolaou smear cytology in the screening settings.
49 Syrjänen K et al. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the new independent states of the former Soviet Union and the Latin American screening study cohorts.
50 Syrjänen KJ, ed. Selected Papers on Gynaecologic Oncology.
51 Syrjänen KJ. Introduction.
52 Syrjänen S et al. Up-regulation of plasminogen activator inhibitor-2 is associated with high-risk HPV and grade of cervical lesion at baseline but does not predict outcomes of high-risk HPV infections or incident CIN.
53 Syrjänen S et al. Immunosuppressive cytokine interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.
54 Syrjänen S et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy.
55 Tvorogov D et al. Somatic mutations of ErbB4. Selective loss-of-function phenotype affecting signal transduction pathways in cancer.
56 Vuoristo M-S et al. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
57 Xavier SD et al. Prevalence of human papillomavirus (HPV) DNA in oral mucosa of men with anogenital HPV infection.
58 Zhang N et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
59 Zucchi F et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma.
Julkaisutietokanta 26.8.2010 Publications Data Base 26.8.2010